Blood serum markers for prostate cancer

Serum markers CA15-3 and CA125 address the inefficiency of current mCRPC monitoring by evaluating AR-negative cells, enhancing diagnostic accuracy and treatment strategies.

JP2024169358APending Publication Date: 2024-12-05UNIVERSITY OF THE RYUKYUS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024082366
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-21
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods for monitoring metastatic castration-resistant prostate cancer (mCRPC) rely heavily on imaging tests to assess AR-negative PC cells, as serum PSA only reflects AR-positive cell proliferation, leading to inefficiencies and increased medical imaging demands.

Method used

Development of serum markers, specifically CA15-3 and CA125, which correlate with the proliferation status of AR-negative prostate cancer cells, allowing for their evaluation and enabling more accurate diagnosis and treatment strategies.

Benefits of technology

Enables the evaluation of AR-negative prostate cancer cells, reducing the need for imaging tests and providing a basis for personalized treatment decisions by quantifying or detecting CA15-3 or CA125 in serum.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169358000001_ABST
    Figure 2024169358000001_ABST
Patent Text Reader

Abstract

To provide blood serum markers that enable evaluation of AR-negative prostate cancer cells of prostate cancer.SOLUTION: A method of using CA15-3 or CA125 as a blood serum marker is provided, the method comprising quantifying or detecting CA15-3 or CA125 in blood serum to diagnose prostate cancer. That is to say that CA15-3 or CA125 (hereunder collectively referred to as "CA15-3, etc.") in blood serum is an indicator reflecting the presence of AR-negative prostate cancer cells. Thus, quantification or detection of CA15-3 or CA125 enables prostate cancer diagnosis.SELECTED DRAWING: Figure 7
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to serum markers for use in the diagnosis of prostate cancer. [Background technology]

[0002] Prostate cancer is the most common malignant tumor in men worldwide. In localized cases, radical treatment such as surgical therapy is possible. On the other hand, in metastatic hormone-sensitive prostate cancer (mHSPC), androgen-deprivation therapy (ADT) has been applied.

[0003] In recent years, the combination of ADT and androgen receptor (AR) targeted drugs or docetaxel has been recommended for mHSPC. More recently, ADT + AR targeted drugs + docetaxel has become covered by health insurance. However, when prostate cancer (mHSPC) cells become resistant to these ADT and AR-targeting drugs, they transition from mHSPC to metastatic castration-resistant prostate cancer (mCRPC).

[0004] It has become clear that the acquisition of resistance to ADT and AR-targeted drugs in mCRPC PC cells is due to reactivation of AR signaling by AR amplification, mutation, splice variant 7 (AR-v7), etc. In addition, loss of AR expression occurs in approximately 20% of CRPC cells, which is believed to be due to lineage plasticity to escape the pressure of suppressive but non-curative treatment. Thus, initially AR-driven PC transitions to CRPC (mixed tumor), which consists of both AR-positive and AR-negative PC cells. As CRPC progresses, not only AR-positive but also AR-negative PC cells proliferate. At this stage of mCRPC, prostate-specific antigen (PSA), in which AR is a transcription factor, only reflects the proliferation status of AR-positive PC cells, and therefore cannot grasp the progression status of AR-negative PC cells. Therefore, in order to monitor the progression status of mCRPC, in addition to measuring serum PSA, regular imaging tests are currently required to check the proliferation status of AR-negative PC cells.

[0005] Incidentally, stage-specific embryonic antigen-4 (SSEA-4), a globoseries ganglioside, was detected in early embryos using monoclonal antibody MC813-70. Subsequently, the inventor, Saito, identified ST3GAL2, an α2,3-sialyltransferase, as the SSEA-4 synthase. Recently, the inventors have reported that SSEA-4 is associated with resistance to androgen deprivation therapy (ADT) in prostate cancer, and that the rate of strong SSEA-4 expression was significantly increased in CRPC tissues, and that a negative correlation was observed between SSEA-4 and AR expression (Non-patent Documents 1, 2). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Yuno, T., et al. (2020). "Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer." Anticancer Res 40(10): 5567-5575. [Non-Patent Document 2] Harada, J., et al. (2021). "Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor." Anticancer Res 41(7): 3327-3335 Summary of the Invention [Problem to be solved by the invention]

[0007] As mentioned above, in order to monitor the progression of mCRPC, regular imaging tests are necessary in addition to serum PSA measurement. Therefore, if there were a serum marker that reflects the proliferation state of AR-negative PC cells, it would be clinically useful because it would be possible to minimize the need for imaging tests. Based on the phenomenon of SSEA-4 expression in AR-negative PC cells, the inventors hypothesized that secreted proteins related to SSEA-4 may be serum markers reflecting the presence of AR-negative PC cells, and therefore began research.

[0008] In light of the above circumstances, an objective of the present invention is to provide a serum marker that enables evaluation of AR-negative prostate cancer cells in prostate cancer. [Means for solving the problem]

[0009] As a result of intensive research, the inventors have demonstrated that MUC1 is expressed in some AR-negative prostate cancer cell lines, and that knocking out the ST3GAL2 gene down-regulates MUC1 expression. Furthermore, the inventors have discovered that serum levels of CA15-3, a soluble protein of MUC1, and CA125, a soluble protein of MUC16, at the time of blood collection are significantly associated with the overall survival rate of mCRPC patients from the time of blood collection, and that serum CA15-3 levels are associated with the time to transition to CRPC (CRPC-free survival rate) in mHSPC patients, thus completing the invention.

[0010] The present invention comprises the following configuration. [1] A method for using a serum marker for diagnosing prostate cancer, the method comprising quantifying or detecting CA15-3 or CA125 in serum as a serum marker. [2] The method of use as a serum marker described in [1], characterized in that the diagnosis is localized prostate cancer, locally advanced prostate cancer, metastatic hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer, or a classification diagnosis thereof. [3] The method of use as a serum marker described in [1], characterized in that the diagnosis is for determining a treatment plan, predicting the effectiveness of treatment, or evaluating the effectiveness of treatment in prostate cancer. [4] A method for using the serum marker described in [1], characterized in that the quantification or detection of the serum marker is performed by any one of ELISA, fluorescent labeling, mass spectrometry, and protein microarray. [5] A method for using the serum as a marker described in any one of [1] to [4], characterized in that the diagnosis comprises estimating the amount of AR-negative PC cells in prostate cancer. [6] A method for using the serum marker described in [5] above, characterized in that it is used in combination with PSA to diagnose prostate cancer. Effect of the Invention

[0011] INDUSTRIAL APPLICABILITY The present invention makes it possible to provide a serum marker that enables the evaluation of AR-negative prostate cancer cells in prostate cancer. [Brief description of the drawings]

[0012] [Figure 1] The figure shows the results of examining the expression of SSEA-4 in parent cells (DU145) and ST3GAL2 gene knockout clones. A shows the results of immunostaining of glycolipids extracted from each cell line using anti-SSEA-4 monoclonal antibody. B shows the results of orcinol staining of the extracted glycolipids. [Diagram 2]FIG. 1 shows the results of an analysis of the number of up- or down-regulated genes in complete knockout clones of the ST3GAL2 gene. [Diagram 3] A diagram showing the strategy for searching for serum marker candidates by knocking out the ST3GAL2 gene. [Figure 4] This figure shows the results of investigating MUC1 expression in each cell line (parent DU145 cell line and knockout clones). [Diagram 5] FIG. 1 shows the results of examining the expression of MUC1, etc. in each prostate cancer cell line. [Figure 6] FIG. 1 shows the results of comparing the expression profiles of AR and various signal proteins in each prostate cancer cell line. [Figure 7] A diagram showing the results of investigating the relationship between serum CA15-3 levels and the stage of progression in prostate cancer. NEM: no evidence of malignancy (no malignant findings proven by biopsy), localized PC (prostate cancer): localized prostate cancer (T2 or less), locally advanced PC: locally advanced prostate cancer (T3-T4), mHSPC: metastatic hormone-sensitive prostate cancer, mCRPC: metastatic castration-resistant prostate cancer [Figure 8] A diagram showing the results of investigating the relationship between serum CA125 levels and the stage of progression in prostate cancer. NEM: no evidence of malignancy (no malignant findings proven by biopsy), localized PC (prostate cancer): localized prostate cancer (T2 or less), locally advanced PC: locally advanced prostate cancer (T3-T4), mHSPC: metastatic hormone-sensitive prostate cancer, mCRPC: metastatic castration-resistant prostate cancer [Figure 9]A graph showing the relationship between serum CA15-3 levels and overall survival in patients with mCRPC. The cutoff values ​​for higher and lower levels are the 75 percentile. [Figure 10] A graph showing the relationship between serum CA125 levels and overall survival in mCRPC patients. The cutoff values ​​for higher and lower levels are the 75 percentile. [Figure 11] This figure shows the results of investigating the relationship between serum CA15-3 levels and the time to progression to CRPC (CRPC-free survival rate) in patients with mHSPC. The cutoff values ​​for higher and lower levels are the 75 percentile. [Figure 12] A graph showing the results of investigating the relationship between serum PSA levels and overall survival in patients with mCRPC. The cutoff values ​​for higher and lower levels are the median values. [Figure 13] Figure showing the relationship between combinations of serum PSA and CA15-3 levels and overall survival in patients with mCRPC. The cutoff values ​​for higher and lower levels are the median (A) or 75th percentile (B) of each marker. A, PSA ≧ cutoff value and CA15-3 ≧ cutoff value; B, PSA ≧ cutoff value and CA15-3 < cutoff value; C, PSA < cutoff value and CA15-3 ≧ cutoff value; D, PSA < cutoff value and CA15-3 < cutoff value. [Figure 14] Figure showing the relationship between combinations of serum PSA and CA125 levels and overall survival in patients with mCRPC. The cutoff values ​​for higher and lower levels are the median (A) or 75th percentile (B) of each marker. A, PSA ≧ cutoff value and CA125 ≧ cutoff value; B, PSA ≧ cutoff value and CA125 < cutoff value; C, PSA < cutoff value and CA125 ≧ cutoff value; D, PSA < cutoff value and CA125 < cutoff value. [Figure 15] A graph showing the time series changes in serum CA15-3 levels. Temporal changes were observed in 18 cases. [Figure 16] Prostate tissues were obtained from 20 patients with mCRPC who underwent transurethral resection of the prostate or radical prostatectomy due to lower urinary tract obstruction. Serial sections were prepared from each paraffin-embedded specimen, and tissue immunostaining was performed with antibodies against AR, MUC1, and CA125 to examine the relationship between AR and MUC1 and CA125 expression. [Figure 17] Same figure 16. [Figure 18] Same figure 16. [Figure 19] Same figure 16. [Figure 20] Same figure 16. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention will now be described in detail. The method of the present invention for using CA15-3 or CA125 in serum as a serum marker is characterized in that prostate cancer is diagnosed by quantifying or detecting CA15-3 or CA125 in serum. That is, the level of CA15-3 or CA125 (hereinafter collectively referred to as "CA15-3, etc.") in serum is an indicator that reflects the presence of AR-negative prostate cancer cells. Among these, the expression of CA15-3 in AR-negative prostate cancer cell lines was demonstrated by Western blotting. On the other hand, based on the phenomenon of SSEA-4 expression in AR-negative prostate cancer cell lines, the mRNA expression of CA125 was linked to the expression of SSEA-4 (=AR-negative), and therefore both serum markers were considered to be markers of AR-negative prostate cancer cells. Based on these experimental facts, it is possible to diagnose prostate cancer by quantifying or detecting CA15-3 or CA125.

[0014] In the present invention, CA15-3 is defined as a soluble protein on the N-terminal side of MUC1 (mucin 1, cell surface associated). In the present invention, CA125 is defined as a soluble protein on the N-terminal side of MUC16 (mucin 16, cell surface associated).

[0015] In the present invention, the diagnosis of prostate cancer does not need to be particularly limited as long as it leads to a qualitative or quantitative evaluation of prostate cancer, and can include various diagnoses. Examples of the types of diagnoses include qualitative diagnosis, quantitative diagnosis, and staging.

[0016] As a typical diagnostic method of the present invention, a diagnosis can be performed to estimate the amount of AR-negative PC cells in prostate cancer. In other words, the amount (level value) of CA15-3 etc. in serum is an indicator of the amount of AR-negative PC cells in prostate cancer, regardless of primary or metastatic. Therefore, it is possible to estimate the amount of AR-negative PC cells in prostate cancer based on the amount of CA15-3 etc. in serum.

[0017] Another diagnostic method of the present invention is diagnosis of the stage of prostate cancer (disease staging). In other words, if the progression of prostate cancer cannot be prevented, it will progress in the following order: localized prostate cancer, locally advanced prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. As the progression of these prostate cancers progresses, serum CA15-3 tends to increase, and a significant difference was observed in serum CA15-3 levels in prostate cancer patients as a whole, divided by stage (Kruskal-Wallis: p<0.0001). On the other hand, serum CA125 levels tend to increase after progression to mCRPC, and a significant difference was observed in serum CA125 levels in prostate cancer patients as a whole, divided by stage (Kruskal-Wallis: p<0.0001). These findings suggest that the stage of prostate cancer can be diagnosed by measuring the amount of CA15-3 and other substances in serum.

[0018] Other diagnostic methods of the present invention include determining a treatment plan (prediction of treatment effect) and assessing treatment effect in prostate cancer. In other words, by measuring the amount of CA15-3 etc. or the PSA measurement described below, it is possible to predict AR-positive and AR-negative prostate cancer cells, the ratio of each type of cancer cell, and determine a treatment plan. For example, if there are many AR-positive prostate cancer cells, AR-targeted drugs will be used primarily, and if there are many AR-negative prostate cancer cells, docetaxel will be used primarily. Furthermore, the effectiveness of treatment can be assessed by measuring changes in CA15-3 levels and PSA levels before and after treatment, and the amount of AR targeted drugs, docetaxel, etc. can be adjusted accordingly.

[0019] Recently, triplet therapy (ADT + AR-targeted drug + docetaxel) has been approved for mHSPC patients. This triplet therapy should be used when both AR-positive and AR-negative PC cells are proliferating, but there are no criteria for this. On the other hand, applying triplet therapy to all mHSPC patients (all comers) would result in greater adverse events (side effects) because unnecessary docetaxel would be administered when AR-negative PC cells are not proliferating. This is also a major problem from the perspective of appropriate use of medical expenses. When applying this combination therapy of ADT, AR targeted drugs, and docetaxel, it makes sense to measure PSA (reflecting the proliferation status of AR-positive PC cells) as well as CA15-3 etc. (reflecting the proliferation status of AR-negative PC cells) and establish appropriate standards. It is expected that CA15-3 etc., the results of this study, will play a major role in establishing standards for adapting triplet therapy.

[0020] In the diagnosis of the present invention, a typical example is the use of CA15-3 in combination with PSA, and by measuring and comparing the quantitative changes in CA15-3 and PSA over time, it is possible to estimate the progression of AR-positive and AR-negative prostate cancer cells in prostate cancer.

[0021] In the present invention, the method for detecting or quantifying CA15-3, etc. in serum does not need to be particularly limited, and various techniques can be used as long as it is possible to detect and quantify CA15-3, etc. Examples of these techniques that can be used include ELISA, fluorescent labeling, mass spectrometry, and protein microarray, and most preferably, ELISA can be used. EXAMPLES

[0022] <<Experimental Example 1, Knockout of the ST3GAL2 gene using CRISPR / Cas9>> Experiments were carried out to establish ST3GAL2 gene knockout prostate cancer cell lines.

[0023] 1. Using CRISPR-Cas9 gene editing technology, we knocked out the ST3GAL2 gene in DU145 cells, an AR-negative prostate cancer cell line. 2. DU145 cells were co-transfected with the gRNA vector and a GFP expression vector containing a puromycin functional cassette. After treatment with puromycin, resistant cell colonies were isolated to establish stable cell lines. All of these clones were confirmed by PCR and Sanger sequencing to have correct chromosomal integration of GFP-Puro DNA into the ST3GAL2 gene site via the homologous recombination site (not shown).

[0024] 3. We also analyzed the target site mutations in the other alleles of these clones by Sanger sequencing of the PCR products. Two partial knockout clones (clones 2 and 5) had one wild-type allele and one ST3GAL2 gene c.1173del mutation, while the other complete knockout clone only had the c.1231_1234del mutation allele (not shown).

[0025] 4. To confirm whether the knockout cell lines had lost sialyltransferase activity, the expression of SSEA-4 was analyzed by high-performance thin layer chromatography (HPTLC) and immunoblotting. (1) Glycolipids were extracted from each cell and separated by thin-layer chromatography. (2) After reacting the TLC plate with anti-SSEA-4 mAb RM1, SSEA-4 was detected using the avidin-biotin system with Clarity Western ECL Substrate (Bio-Rad Laboratories, Inc., Hercules, CA). (3) SSEA-4 expression was not detected in complete knockout clones, including clones 83 and 13 (Figure 1). (4) The two partial knockout clones (clones 2 and 5) showed lower expression levels than the parental cells, DU145 (Figure 1). (5) Furthermore, the orcinol staining results in (B) showed that glycolipids were properly extracted from each cell, and that a band with the same mobility as SSEA-4 (a glycolipid other than SSEA-4) was confirmed in each knockout clone. (6) These results confirmed that the complete knockout clone had lost all sialyltransferase activity, whereas the partial knockout clone had lost only a portion of the sialyltransferase activity. 5. In subsequent experiments, clones 13 and 83 were used as complete knockout clones, and clones 2 and 5 were used as partial knockout clones.

[0026] <<Experimental Example 2, Changes in gene (mRNA) expression in ST3GAL2 gene knockout clones>> For the ST3GAL2 gene knockout clone obtained in Experimental Example 1, an experiment was carried out to examine gene (mRNA) changes.

[0027] 1. To characterize and compare the transcriptional signatures associated with ST3GAL2 gene knockout, whole-exome sequencing analysis was performed in the two knockout clones compared to control cells (parental DU145 cells). 2. Compared with DU145 cells, the numbers of down-regulated genes in knockout clones 13 and 83 were 171 and 236, respectively, and the numbers of up-regulated genes were 80 and 179, respectively (Fold change |Fc|>=2 and raw p-value<0.05) (Figure 2).

[0028] 3. The inventors have reported that there is a negative correlation between SSEA-4 and AR expression in CRPC tissues (Non-Patent Document 2). In other words, based on the knowledge that SSEA-4 is expressed in AR-negative PC cells, we considered that the secretory protein (SSEA-4-related secretory protein) whose mRNA level was decreased with the disappearance of SSEA-4 in the knockout clone could be a candidate serum marker for AR-negative PC cells (Figure 3). 4. Among the down-regulated genes encoding secreted proteins, we focused on MUC1 and MUC16 (Table 1). (1) In knockout clone 83, the value for MUC1 was -33.5, which means that MUC1 mRNA was downregulated 33.5-fold in knockout clone 83 compared to that in parental DU145 cells. Similarly, the value for MUC16 was -14.6. (2) In knockout clone 13, MUC1 and MUC16 were down-regulated, with values ​​of -18.2 and -6.4, respectively.

[0029] [Table 1]

[0030] <<Experimental Example 3, Changes in the expression levels of MUC1 and MUC16 (CA125) in ST3GAL2 gene knockout clones>> 1. To clarify whether the expression of MUC1 and MUC16 is related to ST3GAL2, the expression levels of each protein in knockout clones were analyzed by Western blotting.

[0031] 2.The results are shown in Figure 4. (1) Strong expression of the N-terminal region of MUC1 was detected in DU145 cells, the parental cells of each clone. (2) In contrast, in the ST3GAL2 gene partial knockout clones, clones 2 and 5, weak to faint MUC1 expression was confirmed. (3) In addition, in clone 83, which is a complete ST3GAL2 gene knockout clone, the expression level of MUC1 was found to be weak or not expressed at all. (4) Furthermore, CA125, which is widely used as a tumor marker, was not detected in either the knockout or parent DU145 (not shown). 3. These results demonstrated that knockout of the ST3GAL2 gene significantly reduced MUC1 protein expression.

[0032] <<Experimental Example 4, Relationship between MUC1 and AR expression in prostate cancer cell lines>> 1. We conducted experiments to investigate the relationship between MUC1 expression and AR expression in various prostate cancer cell lines.

[0033] 2.The results are shown in Figure 5. (1) MUC1 was strongly expressed in DU145 and AICaP1, in which AR expression was not detected. (2) MUC1 expression was almost nonexistent in AR-negative PC3 cells, and little or no MUC1 expression was observed in the neuroendocrine prostate cancer (NEPC) cell lines NCI-H660 and KUCaP13. (3) These results indicate that some AR-negative prostate cancer cell lines express MUC1. (4) On the other hand, expression of CA125 was low in the prostate cancer cell lines examined. This suggests that the CA125 detected in the sera of mCRPC patients may have been derived from other cells, or that because CA125 has a large number of glycans bound to it, the anti-CA125 antibody used was blocked by the glycans bound to CA125 in the cell lysate and could not properly detect CA125, whereas the presence of exoglycosidase in serum may have caused the outer glycans of the CA125-bound glycans in serum to be released, allowing the anti-CA125 antibody to approach and detect CA125.

[0034] 3. Furthermore, the results of investigating the expression of major signal molecules in each cell are shown in Figure 6. Although the number of signal molecules examined was not large, similar molecular profiling, including MUC1 expression, was observed between DU145 and AICaP1. In other words, it was suggested that AR-negative prostate cancer cells may be classified into certain types. At the cell line level, except for neuroendocrine prostate cancer, they are classified into the DU145 & AICaP1 group and the PC3 group. AICaP1 is an AR-negative line induced by the study representatives from AR-positive LNCaP under androgen deprivation, and is highly malignant compared to LNCaP ( [Non-Patent Document 2] Harada, J., et al. Anticancer Res 2021.) This induction experiment is similar to the situation in which prostate cancer cells that have lost AR appear when ADT treatment becomes ineffective and the cancer progresses to CRPC in clinical settings, and the fact that CA15-3 was detected in serum also suggests that AR-negative cancer cells can be classified to a certain extent.

[0035] <<Experimental Example 5, Relationship between serum marker levels and stage of prostate cancer>> 1. The purpose of this study was to investigate the relationship between the serum markers MUC1 and MUC16 and the stage of progression of prostate cancer, and to determine whether each serum marker is useful as a serum marker for prostate cancer.

[0036] 1. The results of analyzing the relationship between each serum protein and the progression stage of prostate cancer are shown in Figures 7 and 8. (1) Serum CA15-3 levels showed significant differences across patients with various stages of prostate cancer (p<0.0001, Fig. 7). Serum CA15-3 levels also tended to gradually increase as the stage of prostate cancer progressed. (2) Similarly, serum CA125 levels also showed significant differences across patients with various stages of prostate cancer (p<0.0001, Figure 8). Although there was no clear trend toward increased serum CA125 levels according to prostate cancer stage, as seen with CA15-3, there was a tendency for serum CA125 levels to increase with progression to mCRPC.

[0037] 2. The results of an analysis of the relationship between serum CA15-3 or CA125 levels and survival rate in patients with metastatic castration-resistant prostate cancer are shown in Figures 9 and 10. (1) Serum CA15-3 levels at the time of blood collection were significantly associated with overall survival rate from the time of blood collection in mCRPC patients (p = 0.0002) (Figure 9: Kaplan-Meier curve showing overall survival rate from the time of blood collection in mCRPC patients). (2) Serum CA125 levels at the time of blood draw were also significantly associated with overall survival from the time of blood draw in mCRPC patients (p=0.0002) (Figure 10: Kaplan-Meier curve showing overall survival from the time of blood draw in mCRPC patients). (3) The levels of each serum marker were stratified into high or low groups based on their 75% quartiles. (4) The patient background used in the survival curves (the clinicopathological background of 59 mCRPC patients for whom the relationship between serum CA15-3, CA125, and PSA levels and overall survival rate could be examined) is shown in Table 2.

[0038] [Table 2]

[0039] 3. The results of an analysis of the relationship between serum CA15-3 levels in mHSPC patients and the time to progression to CRPC (when the patient no longer responds to ADT-based treatment and progresses to mCRPC) are shown in Figure 11 (Kaplan-Meier curve showing the CRPC-free survival rate of mHSPC patients). (1) In mHSPC patients, serum CA15-3 levels at the time of initial diagnosis and before the start of treatment were significantly associated with the transition time from initial diagnosis to CRPC in mHSPC patients (p=0.0401, Figure 11). (2) In addition, serum CA15-3 levels were stratified into high and low groups based on the 75% quartile.

[0040] 4. The Kaplan-Meier curves of overall survival rates of metastatic castration-resistant prostate cancer patients according to serum PSA levels are shown in Figure 12. (1) Patients with high PSA levels had a significantly lower survival rate (p=0.0019). (2) PSA levels were stratified by median.

[0041] 5. Kaplan-Meier curves of overall survival rates of patients with metastatic castration-resistant prostate cancer according to the combination of serum PSA and serum CA15-3 levels are shown in Figures 13(A) and (B). (1) PSA and CA15-3 levels were stratified using the median (Fig. 13(A)) or the 75th percentile (Fig. 13(B)) as cutoff values ​​to create combination groups (A, B, C, D): A, PSA ≥ cutoff value and CA15-3 ≥ cutoff value; B, PSA ≥ cutoff value and CA15-3 < cutoff value; C, PSA < cutoff value and CA15-3 ≥ cutoff value; D, PSA < cutoff value and CA15-3 < cutoff value. (2) In all combinations stratified by the median and 75th percentile cutoff values, the group of patients with high PSA and CA15-3 levels (A) had the poorest survival rate compared to the other combinations. On the other hand, the group with both low levels showed a good survival rate. Significant differences were observed between the groups: combination stratified by median (p=0.0074) (Figure 13(A)); combination stratified by 75th percentile (p<0.0001) (Figure 13(B)).

[0042] 6. Kaplan-Meier curves of overall survival rates of patients with metastatic castration-resistant prostate cancer according to the combination of serum PSA and serum CA125 levels are shown in Figures 14(A) and (B). (1) PSA and CA125 levels were stratified using the median (Fig. 14(A)) or the 75th percentile (Fig. 14(B)) as cutoff values ​​to create combination groups (A, B, C, D). A, PSA ≥ cutoff value and CA125 ≥ cutoff value; B, PSA ≥ cutoff value and CA125 < cutoff value; C, PSA < cutoff value and CA125 ≥ cutoff value; D, PSA < cutoff value and CA125 < cutoff value. (2) In both combination groups stratified by the median and 75th percentile cutoff values, patients with high PSA and CA125 levels (A) had the poorest survival rates compared to other combinations. On the other hand, patients with low levels of both had good survival rates. Significant differences were observed between groups: combination stratified by median (p=0.0031) (Figure 14(A)); combination stratified by 75th percentile (p<0.0001) (Figure 14(B)). (3) When PSA and CA125 were stratified using the 75th percentile as the cutoff value, there was a tendency for the prognosis to be divided into two groups: those with high values ​​for either marker or both were high had a poor prognosis, while those with low values ​​for both markers had an extremely good prognosis.

[0043] 7. Time series changes in serum CA15-3 were observed in 18 patients with metastatic castration-resistant prostate cancer (Fig. 15). Serum CA15-3 increased over time in 12 patients and decreased in 6 patients. (1) It has been suggested that it may change with treatment and reflect progression, and therefore may be used for monitoring. (2) However, no correlation with treatment methods was found in this study.

[0044] 8. The expression relationship of AR, MUC1, and CA125 in 20 cases of CRPC tissue (surgically obtained prostate tissue) was evaluated using serial sections of paraffin-embedded specimens. Five locations per case were randomly selected (total of 100 locations), and each staining property (positive staining of 5% or more was judged as positive) was evaluated. Examples of immunostaining are shown in Figures 16 to 20. Patient background (clinicopathological background of 20 mCRPC patients from whom prostate tissue was obtained by surgery) is shown in Table 3. (1) Figure 16 shows an example in which both MUC1 and CA125 are positively expressed in almost 100% of AR-negative prostate cancer cells. The upper panel for CA125 shows positive expression in black and white, making it difficult to see. (2) Figure 17 shows examples of AR-negative prostate cancer cells in which MUC1 is expressed almost 100%, but CA125 is either negative (upper panel) or partially positive (lower panel: difficult to see due to black and white). (3) Figure 18 shows an example of AR-negative prostate cancer cells in which MUC1 is partially expressed but CA125 is negative. (4) Figure 19 shows an example of AR-positive prostate cancer cells that are both MUC1 and CA125 negative. (5) Figure 20 shows that AR-positive prostate cancer cells are almost 100% positive for MUC1, but the expression of MUC1 is slightly weaker than that of AR. On the other hand, CA125 expression is negative. (6) The relationship between AR and MUC1 expression in serially sectioned prostate cancer cells was evaluated and found to be significantly inversely correlated (Table 4: Table showing the relationship between AR and MUC1 expression in CRPC tissue (prostate) sections) (p<0.0001, chi-square test). The average positive expression rates of MUC1 in 40 AR-negative prostate cancer sites were 56% and 59%, respectively, as calculated visually by two collaborators who are not the inventors of this application. (7) When the expression relationship between AR and CA125 in serial sections of prostate cancer cells was evaluated, a significant inverse correlation was found, as with CA15-3 (Table 5: Table showing the expression relationship between AR and CA125 in CRPC tissue (prostate) sections) (p<0.0036, chi-square test). The CA125 positivity rate in CRPC prostate tissue was only 13%, but in serum, 26% (17 / 65, Figure 8) had high CA125 levels, suggesting the possibility that CA125 expression is increased in distant metastatic lesions. However, bone metastatic lesions were not available, and CA125 expression in distant metastatic lesions could not be examined.

[0045] [Table 3]

[0046] [Table 4]

[0047] [Table 5]

[0048] <<Summary>> 1. We succeeded in generating cells in which the ST3GAL2 gene was knocked out in the AR-negative prostate cancer cell line DU145. 2. Among the multiple genes that were down-regulated in ST3GAL2 gene knockout cells, we focused on MUC1 and MUC16, which are genes encoding secretory proteins. 3. MUC1 expression was observed in some AR-negative PC cell lines, but not in AR-positive PC cell lines. Immunostaining in CRPC prostate tissue also showed a significant inverse correlation between AR and MUC1 expression, and between AR and CA125 expression. The expression rate of MUC1 was particularly high (56-59%) in AR-negative sites, and it was considered to be one of the markers representing AR-negative cancer in CRPC. 4. MUC1 expression was downregulated at both the mRNA and protein levels by knocking out the ST3GAL2 gene in parental AR-negative PC cells, indicating that ST3GAL2 is an upstream regulator of MUC1 in AR-negative PC cell lines. 5. The expression levels of CA15-3, a soluble protein of MUC1, and CA125, a soluble protein of MUC16, in serum at the time of blood collection were significantly correlated with the overall survival rate of mCRPC patients from the time of blood collection. Among the combinations of PSA and CA15-3 or CA125, patients with high levels of both (PSA and CA15-3 or CA125) (either when stratified using the median or the 75th percentile as cutoff values) had the poorest prognosis compared with other combinations, while patients with low levels of both had a good prognosis. These results suggest that the combination of PSA and CA15-3 or CA125 provides a more accurate prognostic prediction than either of these alone. 6. These results indicate that CA15-3 and CA125 are useful markers to complement the inability of PSA to detect AR-negative PC cells.

Claims

1. A method of using a serum marker for diagnosing prostate cancer, comprising: Quantitatively detect or measure CA15-3 or CA125 in serum as a serum marker A method for using the compound as a serum marker.

2. The diagnosis is Localized prostate cancer, locally advanced prostate cancer, metastatic hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer, or a classification of these diagnoses 2. The method for use as a serum marker according to claim 1.

3. The diagnosis is In prostate cancer, treatment plan decisions, treatment effect predictions, and treatment effect evaluations 2. The method for use as a serum marker according to claim 1.

4. The quantification or detection of the serum markers ELISA, fluorescent labeling, mass spectrometry, or protein microarray 2. The method for use as a serum marker according to claim 1.

5. The diagnosis is Estimating AR-negative PC cell mass in prostate cancer A method for using the serum marker according to any one of claims 1 to 4.

6. Used in conjunction with PSA to diagnose prostate cancer The method for use as a serum marker according to claim 5.